Tenaya Seeks Stockholder Approval for 1-for-10 to 1-for-25 Reverse Split to Avoid Nasdaq Delisting
TNYA is trading near its 52-week low of $0.517 (2.5% above the low).
Summary
Tenaya Therapeutics filed a preliminary proxy seeking approval for a reverse stock split between 1-for-10 and 1-for-25 to regain Nasdaq's $1.00 minimum bid price requirement. The special meeting is set for December 9, 2026, with the compliance deadline on January 25, 2027.
Key Events · Corporate Governance and Compliance · TNYA
-
Reverse Stock Split Proposal
Board seeks approval to effect a reverse split at a ratio between 1-for-10 and 1-for-25, with the exact ratio determined by the board at its discretion.
-
Nasdaq Delisting Risk
Company received a delisting notice in January 2026 for trading below $1.00. After transferring to Nasdaq Capital Market, the compliance deadline is January 25, 2027.
-
Special Meeting Scheduled
Stockholders will vote on the reverse split proposal at a virtual special meeting on December 9, 2026. Record date is October 19, 2026.
-
Share Count Impact
At a 1-for-10 ratio, outstanding shares would drop from 227.9M to 22.8M; at 1-for-25, to 9.1M. Authorized shares remain unchanged at 1.0B.
Analysis · TNYA · Life Sciences
Tenaya Therapeutics is asking stockholders to approve a reverse stock split at a ratio between 1-for-10 and 1-for-25. The company received a Nasdaq delisting notice in January 2026 because its stock traded below $1.00 for 30 consecutive business days. After transferring to the Nasdaq Capital Market, the compliance deadline is January 25, 2027. With the stock at $0.53 and near its 52-week low, the reverse split is the primary tool to regain the $1.00 minimum bid price. The board has discretion to choose the exact ratio and to abandon the split entirely. If the split fails to lift the price, delisting to the OTC market would reduce liquidity, limit institutional ownership, and make future capital raises more difficult.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TNYA was trading at $0.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $116.8M. The 52-week trading range was $0.52 to $2.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.